This report was first published by Endpoints News. To see the original version, click here
AccurEdit Therapeutics, a startup based in Suzhou, China, has raised $75 million in Series A funding to advance its growing pipeline of CRISPR-based medicines — among the largest rounds on record for a Chinese gene editing company.
The funding, which hasn’t previously been reported by Western media, closed in September, AccurEdit confirmed to Endpoints News. The investment brings total funding to $116 million since AccurEdit’s founding in 2021.
您已阅读10%（537字），剩余90%（5027字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。